Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
ApexOnco Front Page
Recent articles
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
The company will acquire ImCheck for €350m.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
